Equis ISSN 2398-2977

Equine herpesvirus vaccine

Synonym(s): EHV vaccine

Contributor(s): Rachael Conwell, Prof Derek Knottenbelt, Vetstream Ltd

Introduction

Name

  • Equine herpesvirus vaccine.
  • Two currently marketed in the UK:
    • Equip EHV1,4 (formally Duvaxyn EHV 1,4).
    • Equilis Resequin (combined with influenza virus).

Class of drug

  • Inactivated vaccine.

For further information in the UK see the Horserace Betting Levy Board's Codes of Practice on Equine Herpes Virus.

Description

Chemical name

  • Equip EHV 1,4: contains inactivated EHV-1 strain 438/77 and inactivated EHV-4 strain 405/76; carbopol as adjuvant.
  • Equilis Resequin: contains inactivated EHV-1 strain RAC-H and inactivated EHV-4 strain 2252; preservative sodium timerfonate; traces of antibiotic, ovalbumin and formaldehyde; aluminium hydroxide and ImmunostimTM to enhance immunizing effect.

Physical properties

  • Vaccine inactivated by formaldehyde or ß propionate.

Storage requirements

Store according to manufacturer's recommendations.
  • Usual storage procedures:
    • Refrigerate at 2-8°C/35.6-46.4°F.
    • Do not freeze.
    • Protect from light.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Horses and ponies older than 5 months (ideally all horses in same yard/herd should be vaccinated).
  • Pregnant mares, to reduce the risk of EHV-1 associated abortion.
  • Maiden or barren mares in contact with pregnant mares.
  • Other horses older than 5 months in contact with pregnant mares.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • Do not vaccinate within 4 weeks of receiving immunosuppressive drugs, eg corticosteroids.

with diagnostic tests

  • Seroconversion in response to vaccination is difficult to distinguish from seroconversion as a response to recent infection or carrier status.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMedResource.
  • Paillot R, Case R, Ross J, Newton R & Nugent J (2008) Equine herpes virus-1: virus, immunity and vaccine. Open Vet Sci J 2, 68-91 BenthamOpen (full text pdf).

Other sources of information

  • Horserace Betting Levy Board (2019) Codes of Practice. 5th Floor, 21 Bloomsbury Street, London WC1B 3HF, UK. Tel: +44 (0)207 333 0043; Fax: +44 (0)207 333 0041; Email: enquiries@hblb.org.uk; Website: http://codes.hblb.org.uk.
  • Holmes M A, Townsend H G, Hussey S, Breathnach C, Barnett C, Holland R & Lunn D P (2003) Immune Responses to Commercial Equine Vaccines.In:Proc AAEP Convention. 49, pp 224-226.

ADDED